TY - JOUR
T1 - Patients with axial spondyloarthritis report significant differences between men and women and high impact of the disease
T2 - Large websurvey analysis
AU - Ibáñez Vodnizza, Sebastian E.
AU - van Bentum, Rianne E.
AU - Valenzuela, Omar
AU - van der Horst-Bruinsma, Irene E.
PY - 2020/7
Y1 - 2020/7
N2 - Objective: In axial spondyloarthritis (axSpA), mounting evidence shows female patients to experience a higher disease burden. These differences appear to be particularly large in South America. One explanation could be inequity in treatment access between men and women. The objective was to evaluate gender differences in disease burden and work participation, and the potential influence of treatment, in Latin American patients. Methods: A cross sectional online survey among axSpA patients, collecting disease characteristics, treatment, disease burden (BASDAI, BASFI, ASAS Health Index) and work participation (WPAI). Associations between gender and disease burden or work participation were assessed through regression analyses, correcting for treatment. Results: AxSpA was reported by 472 participants (63% women) and disease activity (BASDAI ≥ 4: 83%), ASASHI (≥ moderately impaired: 91%) and work disability (absenteeism: 41%; presenteeism 82%) were high. Biological use was very low (20%), while 34% used opiates. Females had significantly higher BASDAI, ASAS HI, work absenteeism and presenteeism, although were less likely to receive biologics (26% versus 16%, P < 0.01). Gender differences disappeared after correction for treatment. Conclusions: This web survey in Latin American axSpA patients shows a high disease burden and work impairment. The use of biologics is low, while the use of opiates was alarmingly high. Women used significantly less biologics despite reporting a worse disease state and work disability, which could be due to treatment inequity.
AB - Objective: In axial spondyloarthritis (axSpA), mounting evidence shows female patients to experience a higher disease burden. These differences appear to be particularly large in South America. One explanation could be inequity in treatment access between men and women. The objective was to evaluate gender differences in disease burden and work participation, and the potential influence of treatment, in Latin American patients. Methods: A cross sectional online survey among axSpA patients, collecting disease characteristics, treatment, disease burden (BASDAI, BASFI, ASAS Health Index) and work participation (WPAI). Associations between gender and disease burden or work participation were assessed through regression analyses, correcting for treatment. Results: AxSpA was reported by 472 participants (63% women) and disease activity (BASDAI ≥ 4: 83%), ASASHI (≥ moderately impaired: 91%) and work disability (absenteeism: 41%; presenteeism 82%) were high. Biological use was very low (20%), while 34% used opiates. Females had significantly higher BASDAI, ASAS HI, work absenteeism and presenteeism, although were less likely to receive biologics (26% versus 16%, P < 0.01). Gender differences disappeared after correction for treatment. Conclusions: This web survey in Latin American axSpA patients shows a high disease burden and work impairment. The use of biologics is low, while the use of opiates was alarmingly high. Women used significantly less biologics despite reporting a worse disease state and work disability, which could be due to treatment inequity.
KW - Biologics
KW - Burden
KW - Chile
KW - Gender
KW - Spondyloarthritis
UR - http://www.scopus.com/inward/record.url?scp=85081236269&partnerID=8YFLogxK
U2 - 10.1016/j.jbspin.2020.02.004
DO - 10.1016/j.jbspin.2020.02.004
M3 - Article
C2 - 32109577
AN - SCOPUS:85081236269
VL - 87
SP - 315
EP - 319
JO - Joint Bone Spine
JF - Joint Bone Spine
SN - 1297-319X
IS - 4
ER -